Beam Therapeutics' Edge Against Wave's Trial Data
Beam Therapeutics rallied after Wave Life Sciences' WVE-006 trial data for alpha-1 antitrypsin deficiency (AATD) fell below expectations.
Feed↓
/ What's going on?
Filter:
FDA Reviews Achieve Life Sciences' Cytisinicline for Smoking Cessation
FDA accepted cytisinicline NDA for smoking cessation, with a PDUFA date of June 20, 2026. This marks a significant step, potentially offering the first new FDA-approved therapy in two decades to combat nicotine dependence, supported by strong clinical data and safety.
Macy's Turnaround Takes Hold: Strong Q2 and Lifted Outlook
Macy's reports its first same-store sales growth in 12 quarters, beats Q2 earnings expectations, and raises full-year guidance, signaling its turnaround strategy is gaining traction.
TVA, ENTRA1, and NuScale Power Announce Landmark 6 GW Nuclear Expansion
TVA, ENTRA1, & NuScale partner for 6 GW SMR nuclear expansion to power 4.5M homes or 60 data centers. This public-private initiative boosts energy security, meets soaring demand from AI/tech, and validates NuScale's SMR technology.
Google-Apple Search Deal Survives Antitrust Challenge, Paving Way for AI Collaboration
Judge upheld Google's $20B Apple search deal, avoiding Chrome sale. Google must share search data & end exclusive contracts, a win for both boosting shares. Paves way for AI collaboration, but DOJ weighing options.
Blood Pressure Breakthroughs: Why Mineralys Stock Skyrocketed!
Mineralys shares surged 86% after AstraZeneca announced positive Phase 3 results for its similar blood pressure drug, Baxdrostat. "The results seem slightly worse than Mineralys' Lorundrostat," according to Jefferies. This could lead to business deals for MLYS, which may be "best in class".